XPhyto Therapeutics Corp. to provide an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved in the planning and preparation for the pending human pilot study, the Company announced that its European human CBD bioavailability study will commence in January 2022. XPhyto is developing a hybrid-generic CBD prescription drug formulation that employs the Company's proprietary oral dissolvable (ODF) platform to deliver precise and efficient CBD dosages for the treatment of certain forms of childhood Epilepsy. The US Food & Drug Administration (FDA) and European Medicines Agency (EMA) have approved CBD based medical products from other companies for the treatment of severe childhood forms of Epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. The currently approved and registered formulation of CBD is a lipophilic solution in sesame oil with a standard dosage of 750 mg/day. Due to low bioavailability (approximately 5%) the formulation could be considered highly inefficient compared to the XPhyto ODF platform. For the purpose of carrying out XPhyto's clinical study, the following important and necessary items have been completed or received: Product Development Report, Investigational Medicinal Product Dossier, Permit for Clinical Study, manufacture of clinical product samples; Product Specification File; monitoring agreement; and Import Authorization to the location of the FDA-inspected Clinical Research Center. Pending success in the CBD pilot study, the Company expects to carry out a pivotal clinical study in second half of 2022.